Abbott Laboratories (ABT) 45.70 $ABT
Abbott acquires Topera for USD250m
M2 - Tue Dec 23, 5:27AM CST
Healthcare company Abbott (NYSE:ABT) reported on Monday that it has completed the acquisition of all the outstanding equity of Topera for USD250m upfront, plus potential future payments tied to performance milestones.
ABT: 45.70 (-0.02)
Abbott Completes Acquisition of Topera, Inc.
PR Newswire - Mon Dec 22, 3:30PM CST
Abbott (NYSE: ABT) today announced that it has completed its acquisition of Topera, Inc., a private, venture-backed medical device company focused on developing innovative electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation, one of the most common heart rhythm disorders in the world. Catheter-based electrophysiology is an approximately $3 billion global market that has been growing annually at double-digit rates.
ABT: 45.70 (-0.02)
Buy And Hold Abbott Laboratories
Musings of a Banker - at Seeking Alpha - Mon Dec 22, 2:12PM CST
ABT: 45.70 (-0.02)
Zoetis: Betting The Proverbial Farm?
Marshall Hargrave - at Seeking Alpha - Sat Dec 20, 7:15AM CST
ZTS: 43.84 (+0.87), ABT: 45.70 (-0.02), MRK: 57.46 (+0.25), LLY: 70.16 (+0.42), NVS: 93.91 (+0.66)
7 Stocks Providing Their Shareholders A Growing Income With Higher Cash Dividends
Dividends4Life - at Seeking Alpha - Fri Dec 19, 9:11PM CST
MMM: 166.96 (+0.09), ABT: 45.70 (-0.02), GE: 25.83 (-0.05), PFE: 31.42 (-0.03), LLY: 70.16 (+0.42), O: 49.42 (+0.33), BA: 131.24 (+1.21)
The Dividend Growth Investor's Version Of 'A Christmas Carol'
Chuck Carnevale - at Seeking Alpha - Fri Dec 19, 2:49PM CST
ABT: 45.70 (-0.02), ADP: 85.24 (+0.07), MKC: 76.63 (-0.15), CLX: 105.46 (-0.62), SYY: 40.59 (-0.11), MTB: 126.62 (-0.68), ABBV: 66.21 (+1.86), PG: 93.14 (-0.15), HCBK: 10.18 (-0.07), PEP: 97.09 (-0.27)
Watch for Shares of Abbott Laboratories (ABT) to Approach Resistance at $46.68
Comtex SmarTrend(R) - Fri Dec 19, 9:29AM CST
Shares of Abbott Laboratories (NYSE:ABT) opened today above their pivot of $45.33 and have already reached the first level of resistance at $46.23. Investors may be interested in a cross of the next upside pivot targets of $46.68 and $48.03.
ABT: 45.70 (-0.02)
Does China Have an Unfair Competitive Advantage Over U.S. Companies?
Rich Duprey, The Motley Fool - Motley Fool - Thu Dec 18, 8:00AM CST
Best Buy is taking a fast boat out of China, selling its stake in a local appliance retailer and essentially ending its presence in the country. Photo: Wikimedia Commons. Can U.S. companies beat China, let alone survive or thrive there? Best Buy...
REV: 34.98 (-0.57), ABT: 45.70 (-0.02), AMZN: 303.03 (-3.26), F: 15.30 (-0.03), HD: 103.56 (-0.20), FB: 80.77 (+0.16), WMT: 86.43 (-0.23), BBY: 38.89 (-0.80), GOOG: 528.77 (-1.82), YHOO: 50.65 (+0.63), MJN: 102.04 (+0.48), MCD: 93.83 (-0.39), TWTR: 37.61 (+0.04), MSFT: 48.14 (-0.31), AAPL: 112.01 (-0.53), YUM: 72.79 (+0.11)
Abbott to Present at J.P. Morgan Healthcare Conference
PR Newswire - Thu Dec 18, 8:00AM CST
Abbott (NYSE: ABT) will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2015. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentation on the company at 10:30 a.m. Central time.
ABT: 45.70 (-0.02), JPM: 62.48 (unch)
Philips Buying Volcano To Boost Image-Guided Therapy
at Investor's Business Daily - Wed Dec 17, 5:52PM CST
Diversified Dutch giant Royal Philips (PHG) agreed to acquire San-Diego-based medical imaging company Volcano for $1.2 billion in cash Wednesday, sending the latter's stock up 55% in morning trading in the stock market today, near 18. Philips said...
ABT: 45.70 (-0.02), PHG: 29.39 (-0.06), MDT: 74.08 (+0.31), VOLC: 17.95 (+0.02)
Volcano Acquired by Royal Philips for $1.2B: What Wall Street's Saying
at The Street - Wed Dec 17, 2:20PM CST
Volcano Corp. shares surged more than 50% on Wednesday after Royal Philips agreed to acquire the medical technology company for $1.2 billion.
BSX: 13.13 (+0.07), SPNC: 34.50 (+0.59), ABT: 45.70 (-0.02), PHG: 29.39 (-0.06), MDT: 74.08 (+0.31), TRIV: 13.47 (-0.40), VOLC: 17.95 (+0.02), STJ: 66.67 (+0.67), THOR: 32.81 (+0.74), HTWR: 72.62 (+0.02), ELGX: 15.35 (-0.06), ATRC: 18.76 (+0.13), NVDQ: 16.90 (+0.55)
3 U.S. Medical Devices Stocks That Surged in 2014 - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Dec 17, 9:20AM CST
The prospects of the medical devices industry have improved following a Republican victory in the midterm elections.
AGN: 210.12 (+0.95), ABT: 45.70 (-0.02), JNJ: 104.59 (+0.31), MDT: 74.08 (+0.31), CAH: 82.07 (+0.15), CFN: 59.18 (+0.04), EW: 130.75 (+1.17), SWM: 41.49 (-0.44)
Better Big Pharma Spinoff: Zoetis Inc. or AbbVie Inc.?
Brian Orelli, The Motley Fool - Motley Fool - Wed Dec 17, 8:15AM CST
We're approaching two years after Abbott Labs spun off its pharmaceutical division AbbVie and a little less since Zoetis , Pfizer 's animal health division, separated from its patent company. Seems like a good time to see which spinoff...
ZTS: 43.84 (+0.87), ABT: 45.70 (-0.02), SHPG: 209.29 (+0.07), PFE: 31.42 (-0.03), ABBV: 66.21 (+1.86)
These Stocks Just Raised Their Dividends
Eric Volkman, The Motley Fool - Motley Fool - Tue Dec 16, 1:21PM CST
The final weeks of 2014 have seen a raft of dividend hikes. These are making a lot of investors happy -- not only does a raise in a dividend put extra money directly into the pockets of the lucky shareholders, it also can often boost the price of the...
ABT: 45.70 (-0.02), GE: 25.83 (-0.05), COR: 38.83 (+0.43)
Australian Diabetes Management Devices Market 2007 - 2020
M2 - Tue Dec 16, 8:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/k5t2tt/australian) has announced the addition of the "Australian Diabetes Management Devices Market, 2007 - 2020" report to their offering. The Australian Diabetes Management and Diabetes Diagnostic Devices market jumped by $46 million between 2005 and 2013 The market comprises continuous glucose monitors (CGM), self-monitoring blood glucose (SMBG), manual insulin delivery products, glucose test strips, lancets, syringes, insulin pens and insulin pumps. The growth is driven by the high prevalence of diabetes, acceptance and proliferation of advanced patient compliant technologies, increased reimbursement of devices and government subsidy on consumables. Especially, continuous glucose monitors (CGM), self-monitoring blood glucose (SMBG) and manual insulin delivery products exhibited significant market growth. The prevalence of diabetes in Australia has skyrocketed three times to 4.2% over the last 25 years. Around 1 million people in country suffer from diabetes and around 2 million have pre-diabetes. Of these, 11% have type 1 diabetes, 87% have type 2 diabetes and 2% women have gestational diabetes. We estimate that approximately 3.4 million citizens will suffer from diabetes by 2030. This high progression rates in diabetes can be attributed to the growth in elderly population, increased life expectancy, obesity, sedentary life style, unhealthy diet and high stress levels. Further, factors like smoking and physical inactivity have led to increased prevalence of both the types of diabetes in young people. Key Topics Covered: 1. Charts & Tables 2. Australia Market for Diabetes Management Devices (2007-2020) 3. Australia Market for Blood Glucose Monitoring Systems (2007-2020) 4. Australia Market for Insulin Delivery Devices (2007-2020) 5. Recent Global Developments 6. Company and Product Profiles ARKRAY Inc. Abbott Laboratories Animas Corporation Bayer HealthCare AG Becton Dickinson and Company Eli Lilly and Company F. Hoffmann-La Roche AG LifeScan Inc. Medtronic Inc. Novo Nordisk A/S Sanofi S.A. Smiths Medical Terumo Corporation For more information visit http://www.researchandmarkets.com/research/k5t2tt/australian
ABT: 45.70 (-0.02), NVO: 43.80 (+1.08), MDT: 74.08 (+0.31), LLY: 70.16 (+0.42)
2015 Healthcare Sector Predictions
Leonard Yaffe - Seeking Alpha - Tue Dec 16, 5:50AM CST
Below, I shall review my 2013 and 2014 predictions, as well as share my thoughts on the year ahead. Below are my 2014 Predictions: 1. An increase (however modest) of those without prior health insurance, combined with an improving economy, will...
HYH: 42.62 (-0.24), ABT: 45.70 (-0.02), BIIB: 340.89 (+5.13), MCK: 209.79 (+0.58), CAH: 82.07 (+0.15), DPLO: 29.90 (+0.49), PFE: 31.42 (-0.03), KMB: 117.77 (-0.21), HSP: 62.60 (-0.07), CELG: 109.60 (+3.48), JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), CVS: 97.89 (+0.02), AGIO: 109.67 (+2.45), REGN: 400.12 (+6.07)
Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch
M2 - Tue Dec 16, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/xlb7qj/global_chemical) has announced the addition of the "Global Chemical Sensor Market 2015-2019" report to their offering. One major trend upcoming in this market is the increasing demand for medical sensors in biomedical applications. Chemical sensors help in recording of patient data for quick and correct diagnosis during surgical procedures. The Global Chemical Sensor market in the Medical sector is driven by the steadily growing aging population, growing demand for monitoring systems, and point-of-care testing. According to the report, the most important factors driving market growth is the recovery in the automotive sector. The Automotive sector makes use of advanced, high-cost UEGO sensors that help improve vehicle fuel efficiency and performance. Further, the report states that one of the major challenges confronting the market is the long-term stability of chemical sensors. Manufacturing sensors without compromising on the sensitivity or selectivity of the analysis is very challenging for the market vendors. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Global Chemical Sensor Market 08. Market Segmentation by Type 09. Market Segmentation by Application 10. Geographical Segmentation 11. Key Leading Countries 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Vendor Landscape 20. Key Vendor Analysis 21. Other Reports in this Series Companies Mentioned: - ABB - AMETEK - Abbott Laboratories - Alpha MOS - Alphasense - Bayer - City Technology - DENSO - Delphi Automotive - Delphian - Draegerwerk - E2V technologies - Emerson Electric - Figaro Engineering - Freescale Semiconductor - General Electric - Halma - Heraeus Holding - Hoffmann La-Roche - Honeywell International - Horiba - Industrial Scientific - International Sensor Technology - Johnson & Johnson Services - Mine Safety Appliances - NGK Spark Plugs - Nova Biomedical - Ocean Optics - RAE Systems - Robert Bosch - Siemens - Smiths Detection Teledyne Monitor Labs - Thermo Fisher Scientific - United Technologies - Xylem For more information visit http://www.researchandmarkets.com/research/xl...l_chemical
JNJ: 104.59 (+0.31), ABT: 45.70 (-0.02), AME: 53.98 (+0.19), HON: 101.96 (-0.02), UTX: 116.91 (-0.30), EMR: 62.73 (-0.10), DLPH: 73.45 (-0.42)
The Best Of The Best: Top 7 Dividend Aristocrats
Sure Dividend - at Seeking Alpha - Mon Dec 15, 6:55PM CST
Over the past 3 months I have analyzed each of the 54 Dividend Aristocrats. The complete list of Dividend Aristocrats sorted by sector is included in the tables below: Basic Materials Consumer Goods Financials Health Care ...
MKC: 76.63 (-0.15), GPC: 107.62 (-0.21), CAH: 82.07 (+0.15), ED: 66.91 (+0.90), SYY: 40.59 (-0.11), WMT: 86.43 (-0.23), GWW: 256.98 (-0.82), PNR: 66.99 (-0.09), TGT: 74.65 (-0.04), ABBV: 66.21 (+1.86), LOW: 67.51 (-0.43), BCR: 169.10 (-0.44), TROW: 87.34 (-0.25), VFC: 74.63 (-0.01), FDO: 79.14 (-0.01), HRL: 53.08 (-0.17), MHFI: 90.70 (+0.34), ADP: 85.24 (+0.07), ADM: 53.11 (-0.06), SIAL: 137.16 (-0.01), MCD: 93.83 (-0.39), DOV: 74.20 (-0.28), CVX: 113.47 (-0.48), SHW: 264.55 (+1.46), BF.B: 90.41 (+0.40), MMM: 166.96 (+0.09), BDX: 139.90 (+1.44), CLX: 105.46 (-0.62), MDT: 74.08 (+0.31), KMB: 117.77 (-0.21), XOM: 93.78 (-0.81), CB: 104.37 (-0.07), PEP: 97.09 (-0.27), SWK: 97.36 (+0.04), JNJ: 104.59 (+0.31), T: 33.96 (-0.07), CINF: 52.18 (-0.19), PPG: 231.12 (+0.05), WAG: 76.67 (+0.16), APD: 148.58 (unch), ECL: 107.18 (-0.27), KO: 42.94 (-0.03), ABT: 45.70 (-0.02), HCP: 44.00 (-0.45), NUE: 49.33 (-0.22), EMR: 62.73 (-0.10), LEG: 42.40 (+0.19), BMS: 45.96 (-0.12), ITW: 97.11 (-0.10), CTAS: 79.86 (+0.22), PG: 93.14 (-0.15), BEN: 56.99 (-0.14), AFL: 61.94 (unch), CL: 70.47 (-0.53)
Older Relatives At Risk of Malnutrition - How To Spot The Signs As Families Gather This Christmas
PR Newswire Europe - Mon Dec 15, 6:01PM CST
-- New survey* reveals 88 percent of adults in the UK cannot correctly identify the three most common signs of malnutrition[1].
ABT: 45.70 (-0.02)
Pharmaceuticals and Drug Manufacturing Industry Analytics 2014-2021: Extensive Financial Benchmarks, Metrics and Revenue Forecasts - Market to reach $227.6 billion by 2021
M2 - Mon Dec 15, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ggnrfj/pharmaceuticals) has announced the addition of Plunkett Research Ltd's new report "Pharmaceuticals and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Pharmaceuticals and Drug Manufacturing Industry (U.S.) to reach $227.6 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - AbbVie, Inc. - Abbott Laboratories - Amgen Inc - Bristol-Myers Squibb Co - Eli Lilly & Company - Genentech Inc - Gilead Sciences Inc - Johnson & Johnson - Merck & Co Inc - Pfizer Inc For more information visit http://www.researchandmarkets.com/research/gg...aceuticals Source: Plunkett Research Ltd
JNJ: 104.59 (+0.31), ABT: 45.70 (-0.02), GILD: 91.29 (+1.84), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01)
Abbott acquires Topera for USD250m
M2 - Tue Dec 23, 5:27AM CST
Healthcare company Abbott (NYSE:ABT) reported on Monday that it has completed the acquisition of all the outstanding equity of Topera for USD250m upfront, plus potential future payments tied to performance milestones.
ABT: 45.70 (-0.02)
Abbott Completes Acquisition of Topera, Inc.
PR Newswire - Mon Dec 22, 3:30PM CST
Abbott (NYSE: ABT) today announced that it has completed its acquisition of Topera, Inc., a private, venture-backed medical device company focused on developing innovative electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation, one of the most common heart rhythm disorders in the world. Catheter-based electrophysiology is an approximately $3 billion global market that has been growing annually at double-digit rates.
ABT: 45.70 (-0.02)
Buy And Hold Abbott Laboratories
Musings of a Banker - at Seeking Alpha - Mon Dec 22, 2:12PM CST
ABT: 45.70 (-0.02)
Zoetis: Betting The Proverbial Farm?
Marshall Hargrave - at Seeking Alpha - Sat Dec 20, 7:15AM CST
ZTS: 43.84 (+0.87), ABT: 45.70 (-0.02), MRK: 57.46 (+0.25), LLY: 70.16 (+0.42), NVS: 93.91 (+0.66)
7 Stocks Providing Their Shareholders A Growing Income With Higher Cash Dividends
Dividends4Life - at Seeking Alpha - Fri Dec 19, 9:11PM CST
MMM: 166.96 (+0.09), ABT: 45.70 (-0.02), GE: 25.83 (-0.05), PFE: 31.42 (-0.03), LLY: 70.16 (+0.42), O: 49.42 (+0.33), BA: 131.24 (+1.21)
The Dividend Growth Investor's Version Of 'A Christmas Carol'
Chuck Carnevale - at Seeking Alpha - Fri Dec 19, 2:49PM CST
ABT: 45.70 (-0.02), ADP: 85.24 (+0.07), MKC: 76.63 (-0.15), CLX: 105.46 (-0.62), SYY: 40.59 (-0.11), MTB: 126.62 (-0.68), ABBV: 66.21 (+1.86), PG: 93.14 (-0.15), HCBK: 10.18 (-0.07), PEP: 97.09 (-0.27)
Watch for Shares of Abbott Laboratories (ABT) to Approach Resistance at $46.68
Comtex SmarTrend(R) - Fri Dec 19, 9:29AM CST
Shares of Abbott Laboratories (NYSE:ABT) opened today above their pivot of $45.33 and have already reached the first level of resistance at $46.23. Investors may be interested in a cross of the next upside pivot targets of $46.68 and $48.03.
ABT: 45.70 (-0.02)
Does China Have an Unfair Competitive Advantage Over U.S. Companies?
Rich Duprey, The Motley Fool - Motley Fool - Thu Dec 18, 8:00AM CST
Best Buy is taking a fast boat out of China, selling its stake in a local appliance retailer and essentially ending its presence in the country. Photo: Wikimedia Commons. Can U.S. companies beat China, let alone survive or thrive there? Best Buy...
REV: 34.98 (-0.57), ABT: 45.70 (-0.02), AMZN: 303.03 (-3.26), F: 15.30 (-0.03), HD: 103.56 (-0.20), FB: 80.77 (+0.16), WMT: 86.43 (-0.23), BBY: 38.89 (-0.80), GOOG: 528.77 (-1.82), YHOO: 50.65 (+0.63), MJN: 102.04 (+0.48), MCD: 93.83 (-0.39), TWTR: 37.61 (+0.04), MSFT: 48.14 (-0.31), AAPL: 112.01 (-0.53), YUM: 72.79 (+0.11)
Abbott to Present at J.P. Morgan Healthcare Conference
PR Newswire - Thu Dec 18, 8:00AM CST
Abbott (NYSE: ABT) will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2015. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a formal presentation on the company at 10:30 a.m. Central time.
ABT: 45.70 (-0.02), JPM: 62.48 (unch)
Philips Buying Volcano To Boost Image-Guided Therapy
at Investor's Business Daily - Wed Dec 17, 5:52PM CST
Diversified Dutch giant Royal Philips (PHG) agreed to acquire San-Diego-based medical imaging company Volcano for $1.2 billion in cash Wednesday, sending the latter's stock up 55% in morning trading in the stock market today, near 18. Philips said...
ABT: 45.70 (-0.02), PHG: 29.39 (-0.06), MDT: 74.08 (+0.31), VOLC: 17.95 (+0.02)
Volcano Acquired by Royal Philips for $1.2B: What Wall Street's Saying
at The Street - Wed Dec 17, 2:20PM CST
Volcano Corp. shares surged more than 50% on Wednesday after Royal Philips agreed to acquire the medical technology company for $1.2 billion.
BSX: 13.13 (+0.07), SPNC: 34.50 (+0.59), ABT: 45.70 (-0.02), PHG: 29.39 (-0.06), MDT: 74.08 (+0.31), TRIV: 13.47 (-0.40), VOLC: 17.95 (+0.02), STJ: 66.67 (+0.67), THOR: 32.81 (+0.74), HTWR: 72.62 (+0.02), ELGX: 15.35 (-0.06), ATRC: 18.76 (+0.13), NVDQ: 16.90 (+0.55)
3 U.S. Medical Devices Stocks That Surged in 2014 - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Dec 17, 9:20AM CST
The prospects of the medical devices industry have improved following a Republican victory in the midterm elections.
AGN: 210.12 (+0.95), ABT: 45.70 (-0.02), JNJ: 104.59 (+0.31), MDT: 74.08 (+0.31), CAH: 82.07 (+0.15), CFN: 59.18 (+0.04), EW: 130.75 (+1.17), SWM: 41.49 (-0.44)
Better Big Pharma Spinoff: Zoetis Inc. or AbbVie Inc.?
Brian Orelli, The Motley Fool - Motley Fool - Wed Dec 17, 8:15AM CST
We're approaching two years after Abbott Labs spun off its pharmaceutical division AbbVie and a little less since Zoetis , Pfizer 's animal health division, separated from its patent company. Seems like a good time to see which spinoff...
ZTS: 43.84 (+0.87), ABT: 45.70 (-0.02), SHPG: 209.29 (+0.07), PFE: 31.42 (-0.03), ABBV: 66.21 (+1.86)
These Stocks Just Raised Their Dividends
Eric Volkman, The Motley Fool - Motley Fool - Tue Dec 16, 1:21PM CST
The final weeks of 2014 have seen a raft of dividend hikes. These are making a lot of investors happy -- not only does a raise in a dividend put extra money directly into the pockets of the lucky shareholders, it also can often boost the price of the...
ABT: 45.70 (-0.02), GE: 25.83 (-0.05), COR: 38.83 (+0.43)
Australian Diabetes Management Devices Market 2007 - 2020
M2 - Tue Dec 16, 8:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/k5t2tt/australian) has announced the addition of the "Australian Diabetes Management Devices Market, 2007 - 2020" report to their offering. The Australian Diabetes Management and Diabetes Diagnostic Devices market jumped by $46 million between 2005 and 2013 The market comprises continuous glucose monitors (CGM), self-monitoring blood glucose (SMBG), manual insulin delivery products, glucose test strips, lancets, syringes, insulin pens and insulin pumps. The growth is driven by the high prevalence of diabetes, acceptance and proliferation of advanced patient compliant technologies, increased reimbursement of devices and government subsidy on consumables. Especially, continuous glucose monitors (CGM), self-monitoring blood glucose (SMBG) and manual insulin delivery products exhibited significant market growth. The prevalence of diabetes in Australia has skyrocketed three times to 4.2% over the last 25 years. Around 1 million people in country suffer from diabetes and around 2 million have pre-diabetes. Of these, 11% have type 1 diabetes, 87% have type 2 diabetes and 2% women have gestational diabetes. We estimate that approximately 3.4 million citizens will suffer from diabetes by 2030. This high progression rates in diabetes can be attributed to the growth in elderly population, increased life expectancy, obesity, sedentary life style, unhealthy diet and high stress levels. Further, factors like smoking and physical inactivity have led to increased prevalence of both the types of diabetes in young people. Key Topics Covered: 1. Charts & Tables 2. Australia Market for Diabetes Management Devices (2007-2020) 3. Australia Market for Blood Glucose Monitoring Systems (2007-2020) 4. Australia Market for Insulin Delivery Devices (2007-2020) 5. Recent Global Developments 6. Company and Product Profiles ARKRAY Inc. Abbott Laboratories Animas Corporation Bayer HealthCare AG Becton Dickinson and Company Eli Lilly and Company F. Hoffmann-La Roche AG LifeScan Inc. Medtronic Inc. Novo Nordisk A/S Sanofi S.A. Smiths Medical Terumo Corporation For more information visit http://www.researchandmarkets.com/research/k5t2tt/australian
ABT: 45.70 (-0.02), NVO: 43.80 (+1.08), MDT: 74.08 (+0.31), LLY: 70.16 (+0.42)
2015 Healthcare Sector Predictions
Leonard Yaffe - Seeking Alpha - Tue Dec 16, 5:50AM CST
Below, I shall review my 2013 and 2014 predictions, as well as share my thoughts on the year ahead. Below are my 2014 Predictions: 1. An increase (however modest) of those without prior health insurance, combined with an improving economy, will...
HYH: 42.62 (-0.24), ABT: 45.70 (-0.02), BIIB: 340.89 (+5.13), MCK: 209.79 (+0.58), CAH: 82.07 (+0.15), DPLO: 29.90 (+0.49), PFE: 31.42 (-0.03), KMB: 117.77 (-0.21), HSP: 62.60 (-0.07), CELG: 109.60 (+3.48), JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), CVS: 97.89 (+0.02), AGIO: 109.67 (+2.45), REGN: 400.12 (+6.07)
Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch
M2 - Tue Dec 16, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/xlb7qj/global_chemical) has announced the addition of the "Global Chemical Sensor Market 2015-2019" report to their offering. One major trend upcoming in this market is the increasing demand for medical sensors in biomedical applications. Chemical sensors help in recording of patient data for quick and correct diagnosis during surgical procedures. The Global Chemical Sensor market in the Medical sector is driven by the steadily growing aging population, growing demand for monitoring systems, and point-of-care testing. According to the report, the most important factors driving market growth is the recovery in the automotive sector. The Automotive sector makes use of advanced, high-cost UEGO sensors that help improve vehicle fuel efficiency and performance. Further, the report states that one of the major challenges confronting the market is the long-term stability of chemical sensors. Manufacturing sensors without compromising on the sensitivity or selectivity of the analysis is very challenging for the market vendors. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Global Chemical Sensor Market 08. Market Segmentation by Type 09. Market Segmentation by Application 10. Geographical Segmentation 11. Key Leading Countries 12. Buying Criteria 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Vendor Landscape 20. Key Vendor Analysis 21. Other Reports in this Series Companies Mentioned: - ABB - AMETEK - Abbott Laboratories - Alpha MOS - Alphasense - Bayer - City Technology - DENSO - Delphi Automotive - Delphian - Draegerwerk - E2V technologies - Emerson Electric - Figaro Engineering - Freescale Semiconductor - General Electric - Halma - Heraeus Holding - Hoffmann La-Roche - Honeywell International - Horiba - Industrial Scientific - International Sensor Technology - Johnson & Johnson Services - Mine Safety Appliances - NGK Spark Plugs - Nova Biomedical - Ocean Optics - RAE Systems - Robert Bosch - Siemens - Smiths Detection Teledyne Monitor Labs - Thermo Fisher Scientific - United Technologies - Xylem For more information visit http://www.researchandmarkets.com/research/xl...l_chemical
JNJ: 104.59 (+0.31), ABT: 45.70 (-0.02), AME: 53.98 (+0.19), HON: 101.96 (-0.02), UTX: 116.91 (-0.30), EMR: 62.73 (-0.10), DLPH: 73.45 (-0.42)
The Best Of The Best: Top 7 Dividend Aristocrats
Sure Dividend - at Seeking Alpha - Mon Dec 15, 6:55PM CST
Over the past 3 months I have analyzed each of the 54 Dividend Aristocrats. The complete list of Dividend Aristocrats sorted by sector is included in the tables below: Basic Materials Consumer Goods Financials Health Care ...
MKC: 76.63 (-0.15), GPC: 107.62 (-0.21), CAH: 82.07 (+0.15), ED: 66.91 (+0.90), SYY: 40.59 (-0.11), WMT: 86.43 (-0.23), GWW: 256.98 (-0.82), PNR: 66.99 (-0.09), TGT: 74.65 (-0.04), ABBV: 66.21 (+1.86), LOW: 67.51 (-0.43), BCR: 169.10 (-0.44), TROW: 87.34 (-0.25), VFC: 74.63 (-0.01), FDO: 79.14 (-0.01), HRL: 53.08 (-0.17), MHFI: 90.70 (+0.34), ADP: 85.24 (+0.07), ADM: 53.11 (-0.06), SIAL: 137.16 (-0.01), MCD: 93.83 (-0.39), DOV: 74.20 (-0.28), CVX: 113.47 (-0.48), SHW: 264.55 (+1.46), BF.B: 90.41 (+0.40), MMM: 166.96 (+0.09), BDX: 139.90 (+1.44), CLX: 105.46 (-0.62), MDT: 74.08 (+0.31), KMB: 117.77 (-0.21), XOM: 93.78 (-0.81), CB: 104.37 (-0.07), PEP: 97.09 (-0.27), SWK: 97.36 (+0.04), JNJ: 104.59 (+0.31), T: 33.96 (-0.07), CINF: 52.18 (-0.19), PPG: 231.12 (+0.05), WAG: 76.67 (+0.16), APD: 148.58 (unch), ECL: 107.18 (-0.27), KO: 42.94 (-0.03), ABT: 45.70 (-0.02), HCP: 44.00 (-0.45), NUE: 49.33 (-0.22), EMR: 62.73 (-0.10), LEG: 42.40 (+0.19), BMS: 45.96 (-0.12), ITW: 97.11 (-0.10), CTAS: 79.86 (+0.22), PG: 93.14 (-0.15), BEN: 56.99 (-0.14), AFL: 61.94 (unch), CL: 70.47 (-0.53)
Older Relatives At Risk of Malnutrition - How To Spot The Signs As Families Gather This Christmas
PR Newswire Europe - Mon Dec 15, 6:01PM CST
-- New survey* reveals 88 percent of adults in the UK cannot correctly identify the three most common signs of malnutrition[1].
ABT: 45.70 (-0.02)
Pharmaceuticals and Drug Manufacturing Industry Analytics 2014-2021: Extensive Financial Benchmarks, Metrics and Revenue Forecasts - Market to reach $227.6 billion by 2021
M2 - Mon Dec 15, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/ggnrfj/pharmaceuticals) has announced the addition of Plunkett Research Ltd's new report "Pharmaceuticals and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Pharmaceuticals and Drug Manufacturing Industry (U.S.) to reach $227.6 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - AbbVie, Inc. - Abbott Laboratories - Amgen Inc - Bristol-Myers Squibb Co - Eli Lilly & Company - Genentech Inc - Gilead Sciences Inc - Johnson & Johnson - Merck & Co Inc - Pfizer Inc For more information visit http://www.researchandmarkets.com/research/gg...aceuticals Source: Plunkett Research Ltd
JNJ: 104.59 (+0.31), ABT: 45.70 (-0.02), GILD: 91.29 (+1.84), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01)
